FINWIRES · TerminalLIVE
FINWIRES

Walmart Growth Resilient as Exogenous Factors Mask Underlying Bright Spots, RBC Says

By

Walmart (WMT) continues to show strong core business trends despite near-term headwinds, with exogenous factors such as higher fuel costs masking underlying bright spots, RBC Capital Markets said in a Thursday note.

Higher fuel costs weighed on near-term margins, but the company's decision to absorb them is supporting competitiveness and market share gains, while strong performance continued across Walmart US, Sam's Club, and international operations, driven by e-commerce growth and improving unit economics, according to the report.

RBC noted that Walmart's guidance of 4% to 5% Q2 constant currency sales growth and adjusted earnings per share of $0.72 to $0.74, and fiscal 2027 sales growth of 3.5% to 4.5% and EPS of $2.75 to $2.85 was below expectations, while highlighting that fuel costs and consumer pressure continue to weigh on near-term profitability assumptions.

Earnings drivers include advertising, membership income, and international growth, with muted inflation and e-commerce initiatives such as faster delivery, marketplace expansion, and AI tools supporting long-term operating leverage, the report added.

RBC maintained its outperform rating on the stock while lowering its price target to $137 from $140.

Price: $119.77, Change: $-1.57, Percent Change: -1.29%

Related Articles

Wire

Semtech's AI Business Ramp Likely to Lift Fiscal Q1 Results, Oppenheimer Says

Semtech (SMTC) is likely to report "upside" to fiscal Q1 results and fiscal Q2 outlook as demand for its data center artificial intelligence business ramps up, Oppenheimer said in a report emailed Friday.The brokerage said ramping deployments of active copper cables and linear pluggable optics with large cloud service providers, including what it believes is a deployment by Alphabet's (GOOG, GOOGL) Google, are driving growth.Oppenheimer expects the ACC and LPO market to grow at a 90% compound annual growth rate through 2029, according to the report.Semtech's "Infrastructure" segment, which accounts for 33% of revenue, is expected to rise 9% sequentially and 29% year over year, supported by "FiberEdge" products and increasing AI data center demand, the report said. The firm also pointed to "accelerating" demand for LoRa products in Semtech's Industrial segment as "multiprotocol" capabilities expand use cases in robotics, drones and automation.Semtech has "identified a preferred buyer" for its SWIR cellular modules business, and a divestiture could immediately boost earnings per share and raise companywide gross margins to above 60% from just over 50%, Oppenheimer said.Oppenheimer reiterated an outperform rating on Semtech and raised its price target to $150 from $110.Price: $156.39, Change: $+9.86, Percent Change: +6.73%

$GOOG$GOOGL$SMTC
Wire

DocuSign AI-Backed Platform Increasingly Addressing Enterprise Needs, RBC Says

DocuSign's (DOCU) AI-backed platform IAM, initially targeted at mid-market clients, is increasingly addressing enterprise needs, RBC Capital Markets said in a note emailed Friday after attending DocuSign's Momentum conference.RBC said that "enterprise remains early days" for the platform but value is acrruing as the company's clients "do more with the platform over time, and deeper role-specific use cases (sales, procurement, legal)" are on the rise.The IAM platform is seen as "creating more opportunity for partners to add value relative to the legacy e-signature business," the note said.RBC also highlighted that DocuSign is launching an AI assistant as well as autonomous agents that will be able to automate contract reviews, approval routing, and obligation tracking inside the IAM platform. The new features will integrate with tools from Salesforce (CRM), Microsoft's (MSFT) Copilot, and SAP (SAP) and will be deployed in the US starting in the middle of this year, the note said.RBC kept DocuSign's sector perform rating and $55 price target.Price: $49.02, Change: $+0.05, Percent Change: +0.10%

$DOCU
Wire

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

Haemonetics (HAE) is positioned for potential upside as the company has issued conservative fiscal 2027 guidance across its core segments Plasma, Hospital, and Blood Center, BofA Securities said in a note Friday.Analysts highlighted strong plasma collection trends, with US volumes rising high single digits in fiscal Q4, indicating potential upside if momentum continues.In the Hospital segment, the investment firm said vascular closure is improving with stronger commercial execution and blood management technologies are expected to remain a steady growth driver.Some upside is also likely in the Blood Center segment, where management has guided for a mid-single-digit decline, BofA said.Analysts cited potential catalysts, including Japan label expansion for vascular closure, the Japanese Red Cross plasma transition, possible tariff relief, and new products such as Vivasure's PerQseal Elite, with additional plasma innovation potentially supporting growth beyond 2027.BofA upgraded Haemonetics stock to buy from neutral, and raised its price target to $80 from $72.Shares of Haemonetics were up 2.7% in Friday trading.Price: $63.64, Change: $+1.70, Percent Change: +2.74%

$HAE